Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

75.0%

3 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

2 of 0 completed with results

Key Signals

2 with results0

4Total

Not Applicable (2)

P 1 (2)

Terminated3

Withdrawn1

Clinical Trials (4)

Showing 4 of 4 trials

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

Showing all 4 trials